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LETTERS TO THE EDITOR
Clinical trials in Portugal: A
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JThe  decrease  in  the  number  of  clinical  trials  held  in  Portugal
shows  a  loss  of  competiveness  that  is  disturbing.  We  should
focus  on  measures  that  may  recover  the  implementation  of
a  dynamic  clinical  investigation  ﬁeld.
According  to  a  study  of  the  Portuguese  Association  of
Pharmaceutical  Industry  (APIFARMA)  published  in  20131
there  has  been  a  tendency  towards  stagnation  in  the
number  of  Clinical  trials  (CT)  in  Portugal.  Nevertheless,  in
2012  the  market  value  of  CT  in  Portugal  was  D  36  millions.
Looking  at  the  sites  where  the  CT  were  performed,  between
2006  and  2011,  Coimbra  University  Hospital  Centre  (CHUC)
with  158  CT,  North  Lisbon  Hospital  Centre  (CHLN)  with  135
and  São  João  Hospital  Centre  (CHSJ)  with  98  were  the  top
3  institutions.
Compared  to  Cardiology  with  34  CT  from  2009  until  2012,
Pulmonology  had  only  15.  Compared  with  other  countries,
in  2010  Portugal  had  one  of  the  lowest  numbers  of  CT  per
million  inhabitants,  with  10  compared  with  Czech  Republic,
which  achieved  47.2
Recently  the  EU  has  developed  a  register  for  all  the  Clin-
ical  trials  performed  in  Europe.3 Analysing  the  participation
of  Portuguese  centres  in  the  area  of  Pulmonology  from  2006
to  2015,  the  scenario  is  also  not  very  optimistic,  with  a
total  of  15  trials  on  COPD,  7  in  Cystic  Fibrosis  (CF),  55  in
Lung  Cancer  (LC)  and  6  in  Idiopathic  Pulmonary  Fibrosis
(IPF).  This  is  a  long  way  from  the  involvement  of  Greece
and  the  Czech  Republic  with,  respectively,  28  and  68  CT  on
COPD,  4  and  13  CT  on  CF,  77  and  107  on  LC  and  6  and  12
on  IPF.  Moreover,  analysing  the  participation  of  Portuguese
centres  in  CT  on  COPD  (a  disease  with  the  highest  number
of  patients  included  in  CT)  over  the  last  10  years  (Fig.  1),
there  is  an  irregular  pattern  with  a  minimum  of  0  in  2012
and  a  maximum  of  4  in  2014.
What  can  we  do  to  improve?
By  doing  Clinical  trials  we  will  generate  better  quality
data  to  support  our  decisions  in  healthcare.
Scientiﬁc  societies  should  have  a  stronger  commitment
to  the  promotion  and  support  of  the  clinical  investigation
in  Portugal.  By  helping  to  network  with  European  countries
it  will  facilitate  internationalization  and  improvement  in
science.
Through  the  creation  of  dedicated  structures  and
enhancement  of  cooperation  between  Portuguese  centres
the  results  will  appear  in  the  future.
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2006--2015).
Models  that  include  incentives  for  the  participation
f  researchers  and  other  medical  professionals  should  be
ommon  practice.  Investigator-driven  CT  should  be  also
ncouraged  and  welcomed.
If  we  succeed  in  improving  these  ﬁgures,  the  Portuguese
conomy  will  be  stronger,  we  will  increase  our  small  foot-
rint  in  the  European  respiratory  science  and  our  specialty
ill  have  a  higher  proﬁle.
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